Mendelian randomization analysis reveals potential causal relationships between serum lipid metabolites and prostate cancer risk
Authors:
Open Access
- 24 April 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Abstract
Background Prostate cancer is a common malignancy in men, with its pathogenesis not yet fully elucidated. Recent years have seen increased attention on the relationship between lipid metabolism abnormalities and prostate cancer risk. This study aims to explore the potential causal relationships between serum lipid metabolites and prostate cancer risk using Mendelian randomization methods. Methods This study employed Mendelian randomization methods to analyze the relationship between various serum lipid metabolites (including phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, etc.) and prostate cancer risk using GWAS datasets from the UK Biobank. The research analyzed data from 182,625 participants of European descent, including 9132 prostate cancer cases and 173,493 controls. Multiple statistical methods were used for analysis, including inverse variance weighted method, MR Egger regression method, and weighted median approach. Results were presented through forest plots, funnel plots, and scatter plots. Results The study found that most serum lipid metabolites likely do not have strong causal relationships with prostate cancer risk. However, some metabolites showed weak associations: phosphatidylethanolamine (16:0_20:4) levels demonstrated a weak negative correlation with prostate cancer risk, while phosphatidylinositol (18:0_20:4) levels showed a weak positive correlation. The consistency of results across most analytical methods enhanced the reliability of these findings. Conclusion This study provides important insights into the complex relationship between serum lipid metabolites and prostate cancer risk. Although most lipid metabolites may not be strong determinants of prostate cancer risk, certain specific metabolites may have weak associations.Keywords
This publication has 30 references indexed in Scilit:
- Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST TrialEuropean Urology Focus, 2024
- Kaempferol modulates ɑ2M secretion in bone marrow-derived macrophages by downregulating GR/PER1-mediated lipid metabolism to attenuate the emotional stress-aggravated metastasis of prostate cancerJournal of Ethnopharmacology, 2024
- Application of MRI imaging technology based on magnetic nanoparticles in diagnosis and prognosis evaluation of prostate cancerSLAS Technology, 2024
- Prostate cancer prognosis using machine learning: A critical review of survival analysis methodsPathology - Research and Practice, 2024
- Structure‐Activity Relationships in Supramolecular Hosts Targeting Bacterial Phosphatidylethanolamine (PE) LipidsChemistry – A European Journal, 2024
- Assessing the causal relationship between gut microbiota and prostate cancer: A two-sample Mendelian randomization studyUrologic Oncology: Seminars and Original Investigations, 2024
- Cold-induced phosphatidylethanolamine synthesis in liver and brown adipose tissue of miceBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2024
- Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation TherapyACS Pharmacology & Translational Science, 2024
- DNA aptamer-conjugated lipid nanoparticle for targeted PTEN mRNA delivery to prostate cancer cellsInternational Journal of Pharmaceutics, 2024
- Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization studyCancer Pathogenesis and Therapy, 2024